The BIN3 Knockout A-549 Polyclonal Cells are a heterogeneous pool of CRISPR/Cas9-edited A-549 lung adenocarcinoma epithelial cells engineered to disrupt the BIN3 gene. This polyclonal knockout population provides a robust loss-of-function model for studying BIN3-dependent cellular processes without the need for single-cell cloning, enabling high-throughput and physiologically relevant experimental designs. The cells are supplied as a mixed population of edited alleles, reflecting the complexity of endogenous gene disruption.
The A-549 host cell line was originally isolated from the alveolar basal epithelium of a 58-year-old Caucasian male with lung adenocarcinoma. These adherent epithelial cells retain key characteristics of type II pneumocytes and are widely employed in cancer biology, drug discovery, and toxicology research. Their well-documented genotype and stable growth properties make them a reliable platform for investigating gene function in lung cancer and related carcinomas.
BIN3 encodes a BAR (Bin/Amphiphysin/Rvs) domain-containing protein implicated in membrane curvature sensing and remodeling, endocytosis, and cytokinesis. Mechanistically, BIN3 functions as a tumor suppressor by interacting with DLC1 (Deleted in Liver Cancer 1), a RhoGAP protein, to inhibit RhoA activity. This interaction suppresses RhoA-mediated actin stress fiber formation and cell contractility, thereby restraining cell migration and invasion. BIN3 is also linked to cortactin-mediated actin dynamics, and its activity may be regulated by phosphoinositide binding and upstream small GTPases such as Cdc42 and Rac1. The BIN3/DLC1/RhoA signaling axis converges on downstream effectors including ROCK and the actin cytoskeleton, coordinating membrane trafficking and cytoskeletal organization.
In the context of A-549 lung adenocarcinoma cells, disruption of BIN3 is expected to relieve suppression of RhoA signaling, leading to enhanced actin polymerization, stress fiber formation, and potentially increased migratory and invasive capacity. Given BIN3??s tumor-suppressive roles reported in lung adenocarcinoma and hepatocellular carcinoma, this knockout model provides a relevant platform for dissecting the molecular mechanisms that drive cancer progression. The polyclonal nature of the knockout pool may better recapitulate tumor heterogeneity, allowing for the assessment of BIN3 loss in a cell population rather than a clonal isolate.
Researchers can utilize these BIN3 knockout polyclonal cells in a variety of functional assays to investigate cell migration, invasion, endocytosis, and cytokinesis. Western blotting can confirm BIN3 depletion and assess levels of DLC1 and RhoA, while RhoA activation assays (e.g., G-LISA) and phalloidin staining for F-actin provide direct readouts of RhoA pathway activity. Endocytosis can be monitored using transferrin uptake assays, and proliferation can be measured via standard methods. These cells are suitable for both mechanistic studies and drug screening campaigns targeting the BIN3-DLC1-RhoA signaling module. For additional information, please contact Ascent Research.
